Memantine (Axura)
Substance developed by the Merz research organization used to treat dementia and Alzheimer's Disease.
memantine.com - Mode of Action
Mode of Action. Memantine as an NMDA receptor antagonist can prevent the pathological ... Mode of action of memantine (Interactive animation) ...
Memantine - Pubdrug
Memantine. From Pubdrug. Jump to: navigation, search. Contents. 1 Description. 2 Mechanism of Action. 3 Time Required for Therapeutic Response. 4 Pharmacokinetics ...
Namenda (Memantine), Alzheimer's medication
Namenda (Memantine)is a medication used in the treatment ... Mechanism of Action and ... Memantine is postulated to exert its therapeutic effect through ...
Memantine
Hypersensitivity to memantine or any component of the formulation ... Store at controlled room temperature of 15°C to 30°C (59°F to 86°F). Mechanism of Action: ...
Studies on the mechanism of action of the antiparkinsonian drugs ...
Studies on the mechanism of action of the antiparkinsonian drugs memantine and a ... data on memantine supporting its mechanism of action and promising profile ...
Namenda (memantine HCl) - Drug information from MediLexicon
Drug information and side-effects for Namenda (memantine HCl) ... Side Effects | Mechanism of Action | Literature References ... Mechanism of Action ...
FDA Approves Memantine (Namenda) for Alzheimer's Disease
Memantine's mechanism of action is different from that of the drugs currently ... Although memantine helps treat the symptoms of Alzheimer's Disease in some ...
Namenda (memantine)
of medications with a mechanism of action that is very different from that of ... Moreover, the sedative effects of alcohol may act as a depressant, obscuring the ...
Ebixa / Memantine | Mechanism of action of memantine
The principal mechanism of action of memantine is believed to be the blockade of ... The unusual therapeutic utility of memantine probably results from inhibitory ...
|
Memantine and Down's Syndrome - Full Text View - ClinicalTrials.gov
Home
Search
Study Topics
Glossary
This is a study to assess whether memantine is effective and safe in preventing age related cognitive deterioration and dementia in people with Down's syndrome (DS) age 40 and over. The study will last for a year and it will include 180 people with Down's syndrome with and without dementia. Participants will be assessed on memory skills, attention and problem solving abilities. Quality of life and abilities for everyday living skills will also be regularly checked.